We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
Cap. Flow
-$11.4M
Cap. Flow %
-8.5%
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$2.85M
2
ATEC icon
Alphatec Holdings
ATEC
+$2.84M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$2.84M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$2.12M
5
APLS
Apellis Pharmaceuticals
APLS
+$1.76M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.17M
2
PCRX icon
Pacira BioSciences
PCRX
+$3.36M
3
PFE icon
Pfizer
PFE
+$3.06M
4
UTHR icon
United Therapeutics
UTHR
+$2.79M
5
QURE icon
uniQure
QURE
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 57.92%
2 Real Estate 14.45%
3 Financials 7.05%
4 Industrials 3.2%
5 Technology 2.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AJG icon
126
Arthur J. Gallagher & Co
AJG
$65.2B
$206K 0.15%
731
-52
-7% -$14.7K
PR
127
Permian Resources
PR
$17B
$204K 0.15%
14,966
-202
-1% -$2.97K
CBOE icon
128
Cboe Global Markets
CBOE
$29.1B
$203K 0.15%
989
-68
-6% -$13.4K
AIZ icon
129
Assurant
AIZ
$13.6B
$202K 0.15%
1,017
-37
-4% -$6.74K
MYO icon
130
Myomo
MYO
$34.8M
$201K 0.15%
+50,000
New +$207K
BR icon
131
Broadridge
BR
$17.4B
$200K 0.15%
928
-62
-6% -$13K
TMUS icon
132
T-Mobile US
TMUS
$212B
$199K 0.15%
964
-65
-6% -$12.4K
BRO icon
133
Brown & Brown
BRO
$23.4B
$199K 0.15%
1,917
-132
-6% -$13.1K
CPRT icon
134
Copart
CPRT
$25.5B
$194K 0.14%
3,702
-264
-7% -$13.7K
V icon
135
Visa
V
$686B
$190K 0.14%
690
-47
-6% -$12.7K
TJX icon
136
TJX Companies
TJX
$172B
$190K 0.14%
1,614
-108
-6% -$12.4K
CME icon
137
CME Group
CME
$88.6B
$189K 0.14%
857
-61
-7% -$12.6K
VNQI icon
138
Vanguard Global ex-US Real Estate ETF
VNQI
$3.47B
$189K 0.14%
4,021
-204
-5% -$8.88K
VNQ icon
139
Vanguard Real Estate ETF
VNQ
$39.4B
$184K 0.14%
1,884
-31
-2% -$2.85K
RCL icon
140
Royal Caribbean
RCL
$76.7B
$183K 0.14%
1,029
-28
-3% -$4.54K
ROP icon
141
Roper Technologies
ROP
$36.6B
$182K 0.14%
327
-24
-7% -$13.2K
APH icon
142
Amphenol
APH
$185B
$173K 0.13%
2,650
-182
-6% -$11.8K
FTI icon
143
TechnipFMC
FTI
$28.7B
$167K 0.12%
6,355
-167
-3% -$4.42K
CCL icon
144
Carnival Corporation Ltd
CCL
$35.7B
$151K 0.11%
8,150
-228
-3% -$3.86K
DKNG icon
145
DraftKings
DKNG
$12.1B
$150K 0.11%
3,831
-107
-3% -$3.87K
FXI icon
146
iShares China Large-Cap ETF
FXI
$4.36B
$150K 0.11%
4,705
+111
+2% +$2.94K
RKLB icon
147
Rocket Lab Corp
RKLB
$41.1B
$146K 0.11%
+15,000
New +$91.1K
MCK icon
148
McKesson
MCK
$97.3B
$145K 0.11%
294
-21
-7% -$11.7K
TRML
149
DELISTED
Tourmaline Bio
TRML
$141K 0.11%
5,500
-69,500
-93% -$1.16M
THD icon
150
iShares MSCI Thailand ETF
THD
$361M
$140K 0.1%
+2,023
New +$121K
4 5
6
7 8

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.

  • AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
  • AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
  • AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
  • AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
  • AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
  • AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
  • AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.